Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

PURPOSE The pharmacology and tolerability of exenatide in patients with type 2 diabetes mellitus were studied. METHODS Two randomized, single-blind, placebo-controlled studies were conducted. Treatment with oral antidiabetic agents was stopped 14 days before study initiation. In the first study (study A), eight subjects received placebo, 0.1-, 0.2-, 0.3-, and either 0.4-microg/kg exenatide or placebo five minutes before a meal combined with liquid acetaminophen (to assess the rate of gastric emptying) on days 1, 3, 5, 7, and 9. In the second study (study B), subjects received a single s.c. dose of exenatide or placebo on consecutive days. Part 1 of study B used exenatide doses of 0.01 and 0.1 microg/ kg; 0.02-, 0.05-, and 0.1-microg/kg doses were given in part 2. After an overnight fast, the study drug was injected 15 minutes before a meal (part 1) and before a meal and acetaminophen (part 2). Parts 1 and 2 of study B enrolled six and eight patients, respectively. RESULTS In both studies, plasma exenatide pharmacokinetic profiles appeared dose proportional. Exenatide doses of 0.02-0.2 microg/kg dose-dependently lowered postprandial glucose excursions. Exenatide suppressed postprandial plasma glucagon and slowed gastric emptying. There were no serious adverse events and no patient withdrawals related to treatment. Nausea and vomiting were the most common adverse events and were mild to moderate in severity at doses ranging from 0.02 to 0.2 microg/kg. CONCLUSION Administration of preprandial exenatide by s.c. injection resulted in dose-proportional exenatide pharmacokinetics and antidiabetic pharmacodynamic activity. At doses ranging from 0.02 to 0.2 microg/kg, exenatide dose-dependently reduced postprandial plasma glucose excursion by insulinotropism, suppression of plasma glucagon, and slowing of gastric emptying.

[1]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[2]  G. Green,et al.  Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: role in postprandial hyperglycaemia , 1997, Diabetologia.

[3]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[4]  R. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[5]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[6]  M. Horowitz,et al.  Relationships of upper gastrointestinal motor and sensory function with glycemic control. , 2001, Diabetes care.

[7]  K. Flegal,et al.  Racial and ethnic differences in glycemic control of adults with type 2 diabetes. , 1999, Diabetes care.

[8]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[9]  M. Moore,et al.  Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. , 1996, Reproduction, nutrition, development.

[10]  A. Young,et al.  Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). , 1999, Diabetes.

[11]  A. Young,et al.  Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1 , 2001 .

[12]  A. Baron,et al.  Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. , 2003, Current opinion in investigational drugs.

[13]  A. Young,et al.  Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. , 2001, Metabolism: clinical and experimental.

[14]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[15]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[16]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[17]  M. Adler,et al.  Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment , 1999 .

[18]  J. Egan,et al.  The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. , 2002, The Journal of clinical endocrinology and metabolism.

[19]  Jie Zhou,et al.  Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations , 1999, Diabetologia.

[20]  D. Ziegler Diagnosis and Management of Diabetic Peripheral Neuropathy , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[21]  N. Greig,et al.  Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. , 2000, Endocrinology.

[22]  L F Prescott,et al.  Kinetics of acetaminophen absorption and gastric emptying in man , 1978, Clinical pharmacology and therapeutics.

[23]  Dennis D. Kim,et al.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[24]  J. Henquin,et al.  Triggering and amplifying pathways of regulation of insulin secretion by glucose. , 2000, Diabetes.

[25]  Geert Molenberghs,et al.  Assessing Response Profiles from Incomplete Longitudinal Clinical Trial Data Under Regulatory Considerations , 2003, Journal of biopharmaceutical statistics.

[26]  J. Meyer,et al.  The effect of acute hyperglycemia on gastric emptying in man. , 1976, Gastroenterology.

[27]  S. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[28]  D. Drucker,et al.  Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard* , 1997, The Journal of Biological Chemistry.

[29]  Dennis D. Kim,et al.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. , 2003, Diabetes care.

[30]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[31]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.